Company / EPS (Diluted)
Nuvalent, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$5.85
FY2025
5-year range
-$5.85 / -$1.65
FY2021-FY2025
Trend
-48.9%
vs FY2024
Sector context
#185 of 204
Health Care
What the data says
Among 204 Health Care companies, Nuvalent, Inc. is in the bottom 9% for eps (diluted). EPS (Diluted) has declined for 3 consecutive years, from $-1.65 in FY2022 to $-5.85 in FY2025.
Based on SEC 10-K filings.
-5.85 in FY2025.
Declined from $-2.17 to $-5.85 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 204This company -$5.85 Sector average -$0.89
▼
-560.1% below sector average
Key checks
Key Insights
- Nuvalent, Inc.'s eps (diluted) has declined for 3 consecutive years.
- In FY2025, eps (diluted) decreased 48.9% year-over-year.
- Ranks #185 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.85 | -48.9% |
| FY2024 | -$3.93 | -81.1% |
| FY2023 | -$2.17 | -31.5% |
| FY2022 | -$1.65 | +22.5% |
| FY2021 | -$2.13 | +58.1% |
| FY2020 | -$5.08 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026